Iqvia reports Q4 adjusted EPS $2.84, consensus $2.82

Reports Q4 revenue $3.87B, consensus $3.8B. “The IQVIA team delivered solid 2023 results in a challenging macro environment,” said Ari Bousbib, chairman and CEO of IQVIA. “The TAS segment continued to grow despite persistent client caution and lower spending levels. In R&DS, clinical demand remained strong with double-digit RFP growth and a 1.31 book-to-bill ratio for the quarter. As we begin 2024, the fundamentals of our business and the outlook for our end markets remain healthy.”